Trial Profile
A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Matrix-applied characterised autologous cultured chondrocytes (Primary)
- Indications Knee injuries; Meniscus disorders; Osteonecrosis
- Focus Therapeutic Use
- Acronyms PEAK
- Sponsors Vericel Corporation
- 29 Jun 2023 Planned End Date changed from 1 Jun 2025 to 1 Jun 2027.
- 29 Jun 2023 Planned primary completion date changed from 1 Jun 2025 to 1 Jun 2027.
- 20 Jul 2018 New trial record